Feed ARMP
AR

Armata Pharmaceuticals, Inc.

ARMP · AMEX

$4.91 -11.53% (-$0.64)
1M +23.88%
Market Cap $190.9M
P/E Ratio -
Div. Yield -
ROE -

Bulios Fair Price

$5.3

7.9% upside

Trenutna cena

$4.91

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica ARMP trenutno podcenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Weak
2/9
Valuation
0 /100
Expensive
P/S 57.86x
EV/FFO N/A
P/E N/A
Growth
1 /100
Declining
Rev. growth 3.80%
Book val. growth N/A
EPS growth N/A
Profitability
20 /100
Weak
Op. margin 1,233.59%
Gross margin 68.23%
FCF margin 781.87%
Quality
1 /100
Poor
Asset turnover 0.04x
ROIC 47.40%
ROA 213.65%
Debt
0 /100
High
Int. coverage -7.99x
Current ratio 0.11x
Debt/Assets N/A
Stability
33 /100
Unstable
EPS volatility 479.89%
Beta 1.35x
Profitable years 0

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o ARMP
Online

O podjetju

Armata Pharmaceuticals, Inc. (ARMP) is a biotechnology company focused on developing novel therapeutic options targeting infectious diseases and resistant microorganisms. The company specializes in the use of phage therapy, a method that utilizes bacteriophages, natural predators of bacteria, to combat infections. This innovative technology could offer an alternative to traditional antibiotics, especially in cases of antibiotic resistance. Armata Pharmaceuticals aims to address the challenge of microbial resistance and the need for new treatment approaches. Investors interested in advancements in the treatment of infectious diseases and novel approaches to antibiotic resistance may see potential in Armata Pharmaceuticals, Inc. (ARMP) shares for innovation in the medical industry and improved patient care.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Deborah L. Birx

Employees

61

Headquarters

Los Angeles

Prihajajoči dogodki

11 NOV.

Earnings

Upcoming earnings report

57d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.